tetano
Editor, Senior Moderator
Am J Transplant
. 2023 Mar;23(3):423-428.
doi: 10.1016/j.ajt.2022.11.002. Epub 2023 Jan 12.
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
Andrew H Karaba[SUP] 1 [/SUP], Jake D Kim[SUP] 2 [/SUP], Teresa P-Y Chiang[SUP] 2 [/SUP], Jennifer L Alejo[SUP] 2 [/SUP], Ioannis Sitaras[SUP] 3 [/SUP], Aura T Abedon[SUP] 2 [/SUP], Yolanda Eby[SUP] 4 [/SUP], Trevor Scott Johnston[SUP] 1 [/SUP], Maggie Li[SUP] 3 [/SUP], Tihitina Aytenfisu[SUP] 1 [/SUP], Casey Hussey[SUP] 4 [/SUP], Alexa Jefferis[SUP] 2 [/SUP], Nicole Fortune[SUP] 2 [/SUP], Rivka Abedon[SUP] 2 [/SUP], Letitia Thomas[SUP] 2 [/SUP], Feben Habtehyimer[SUP] 4 [/SUP], Jessica Ruff[SUP] 4 [/SUP], Daniel S Warren[SUP] 2 [/SUP], Robin K Avery[SUP] 1 [/SUP], William A Clarke[SUP] 4 [/SUP], Andrew Pekosz[SUP] 3 [/SUP], Allan B Massie[SUP] 5 [/SUP], Aaron A R Tobian[SUP] 4 [/SUP], Dorry L Segev[SUP] 5 [/SUP], William A Werbel[SUP] 6 [/SUP]
Affiliations
Abstract
Neutralizing antibody (nAb) responses are attenuated in solid organ transplant recipients (SOTRs) despite severe acute respiratory syndrome-coronavirus-2 vaccination. Preexposure prophylaxis (PrEP) with the antibody combination tixagevimab and cilgavimab (T+C) might augment immunoprotection, yet in vitro activity and durability against Omicron sublineages BA.4/5 in fully vaccinated SOTRs have not been delineated. Vaccinated SOTRs, who received 300 + 300 mg T+C (ie, full dose), within a prospective observational cohort submitted pre and postinjection samples between January 31, 2022, and July 6, 2022. The peak live virus nAb was measured against Omicron sublineages (BA.1, BA.2, BA.2.12.1, and BA.4), and surrogate neutralization (percent inhibition of angiotensin-converting enzyme 2 receptor binding to full length spike, validated vs live virus) was measured out to 3 months against sublineages, including BA.4/5. With live virus testing, the proportion of SOTRs with any nAb increased against BA.2 (47%-100%; P < .01), BA.2.12.1 (27%-80%; P < .01), and BA.4 (27%-93%; P < .01), but not against BA.1 (40%-33%; P = .6). The proportion of SOTRs with surrogate neutralizing inhibition against BA.5, however, fell to 15% by 3 months. Two participants developed mild severe acute respiratory syndrome-coronavirus-2 infection during follow-up. The majority of fully vaccinated SOTRs receiving T+C PrEP achieved BA.4/5 neutralization, yet nAb activity commonly waned by 3 months postinjection. It is critical to assess the optimal dose and interval of T+C PrEP to maximize protection in a changing variant climate.
Keywords: COVID-19; Omicron variant; cilgavimab; monoclonal antibody; organ transplant; tixagevimab.
. 2023 Mar;23(3):423-428.
doi: 10.1016/j.ajt.2022.11.002. Epub 2023 Jan 12.
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
Andrew H Karaba[SUP] 1 [/SUP], Jake D Kim[SUP] 2 [/SUP], Teresa P-Y Chiang[SUP] 2 [/SUP], Jennifer L Alejo[SUP] 2 [/SUP], Ioannis Sitaras[SUP] 3 [/SUP], Aura T Abedon[SUP] 2 [/SUP], Yolanda Eby[SUP] 4 [/SUP], Trevor Scott Johnston[SUP] 1 [/SUP], Maggie Li[SUP] 3 [/SUP], Tihitina Aytenfisu[SUP] 1 [/SUP], Casey Hussey[SUP] 4 [/SUP], Alexa Jefferis[SUP] 2 [/SUP], Nicole Fortune[SUP] 2 [/SUP], Rivka Abedon[SUP] 2 [/SUP], Letitia Thomas[SUP] 2 [/SUP], Feben Habtehyimer[SUP] 4 [/SUP], Jessica Ruff[SUP] 4 [/SUP], Daniel S Warren[SUP] 2 [/SUP], Robin K Avery[SUP] 1 [/SUP], William A Clarke[SUP] 4 [/SUP], Andrew Pekosz[SUP] 3 [/SUP], Allan B Massie[SUP] 5 [/SUP], Aaron A R Tobian[SUP] 4 [/SUP], Dorry L Segev[SUP] 5 [/SUP], William A Werbel[SUP] 6 [/SUP]
Affiliations
- PMID: 36906295
- DOI: 10.1016/j.ajt.2022.11.002
Abstract
Neutralizing antibody (nAb) responses are attenuated in solid organ transplant recipients (SOTRs) despite severe acute respiratory syndrome-coronavirus-2 vaccination. Preexposure prophylaxis (PrEP) with the antibody combination tixagevimab and cilgavimab (T+C) might augment immunoprotection, yet in vitro activity and durability against Omicron sublineages BA.4/5 in fully vaccinated SOTRs have not been delineated. Vaccinated SOTRs, who received 300 + 300 mg T+C (ie, full dose), within a prospective observational cohort submitted pre and postinjection samples between January 31, 2022, and July 6, 2022. The peak live virus nAb was measured against Omicron sublineages (BA.1, BA.2, BA.2.12.1, and BA.4), and surrogate neutralization (percent inhibition of angiotensin-converting enzyme 2 receptor binding to full length spike, validated vs live virus) was measured out to 3 months against sublineages, including BA.4/5. With live virus testing, the proportion of SOTRs with any nAb increased against BA.2 (47%-100%; P < .01), BA.2.12.1 (27%-80%; P < .01), and BA.4 (27%-93%; P < .01), but not against BA.1 (40%-33%; P = .6). The proportion of SOTRs with surrogate neutralizing inhibition against BA.5, however, fell to 15% by 3 months. Two participants developed mild severe acute respiratory syndrome-coronavirus-2 infection during follow-up. The majority of fully vaccinated SOTRs receiving T+C PrEP achieved BA.4/5 neutralization, yet nAb activity commonly waned by 3 months postinjection. It is critical to assess the optimal dose and interval of T+C PrEP to maximize protection in a changing variant climate.
Keywords: COVID-19; Omicron variant; cilgavimab; monoclonal antibody; organ transplant; tixagevimab.